文章：

寡转移性非小细胞肺癌的临床见解

Insights on Oligometastatic Non-Small-Cell Lung Cancer

原文发布日期：24 July 2025

DOI: 10.3390/cancers17152451

类型: Article

开放获取: 是

英文摘要：

Oligometastatic non-small-cell lung cancer (OMD-NSCLC) has emerged as a biologically and clinically distinct subtype of advanced disease, characterized by limited metastatic burden and a more indolent course. In this narrative review, we examine the current definition of OMD-NSCLC, diagnostic tests, possible biomarkers, and current therapeutic strategies. Biological insights highlight the role of microRNAs in differentiating true oligometastatic state from polymetastatic disease. The main local ablative therapies (LAT) include surgery and radiotherapy. The integration of LAT with systemic therapies has been explored in clinical trials, yielding promising but occasionally inconsistent results. As the therapeutic landscape of OMD-NSCLC patients continues to evolve, refining definitions, identifying predictive biomarkers, and individualizing care are essential steps toward achieving the potential of radical-intent therapy.

摘要翻译： 

寡转移性非小细胞肺癌（OMD-NSCLC）作为一种生物学和临床特征独特的晚期疾病亚型日益受到关注，其特点在于转移负荷有限且病程相对惰性。本文通过叙述性综述，系统探讨了当前OMD-NSCLC的定义标准、诊断检测方法、潜在生物标志物及现行治疗策略。生物学研究进展揭示了微小RNA在区分真性寡转移与多发性转移中的关键作用。局部消融治疗主要包括外科手术与放射治疗。临床试验已探索局部消融治疗与全身治疗的联合应用模式，虽取得令人鼓舞的成果，但疗效仍存在不一致现象。随着OMD-NSCLC治疗格局的持续发展，完善疾病定义、确立预测性生物标志物及实现个体化诊疗，将成为实现根治性治疗潜力的关键路径。

原文链接：

Insights on Oligometastatic Non-Small-Cell Lung Cancer